UK clears new Moderna vaccine targeting Omicron variant | Inquirer News

UK clears new Moderna vaccine targeting Omicron variant

/ 09:08 PM August 15, 2022
Moderna vaccine

A medical staff member prepares a syringe with a vial of the Moderna Covid-19 vaccine at a pop up vaccine clinic at the Jewish Community Center on April 16, 2021 in the Staten Island borough of New York City. (Photo by Angela Weiss / AFP)

London, United Kingdom — The UK’s drug regulator said Monday it had approved an updated Moderna vaccine against Covid-19 that targets the Omicron variant as well as the original form of the virus.

The Medicine and Healthcare products Regulatory Agency (MHRA) said in a statement said it had approved the vaccine for adult booster doses “after it was found to meet the UK regulator’s standards of safety, quality and effectiveness.”


It was the first such “bivalent” Covid-19 vaccine to be approved by the British regulator.

The MHRA’s chief executive June Raine said data from a clinical trial had shown it prompted a “strong immune response” against the original virus and Omicron and would provide a “sharpened tool in our armory” as the virus kept evolving.


Moderna’s CEO Stephane Bancel said in a statement that the US biotech company was “delighted” by the decision, “the first authorization of an Omicron-containing bivalent vaccine.”

While vaccines have helped lower hospitalizations and deaths from Covid, which first emerged in China in late 2019, the current jabs are mainly aimed at the earlier strains of the disease.

The World Health Organization warned in July that the pandemic was “nowhere near over,” due to the spread of Omicron subvariants and to the lifting of control measures.

Half of the Moderna vaccine targets the original 2020 virus and half the Omicron variant, which is officially known as BA.1.

‘Bivalent’ vaccines

The MHRA said the vaccine was also found to generate a “good response” against two Omicron subvariants, BA.4 and BA.5, which have partly driven a wave of new cases of the disease in Europe and the United States.

The vaccine had the same “typically mild” side effects as the original Moderna jab, it added.

Moderna said in June that its “bivalent” vaccine performed better against both Omicron and the original virus compared to its original Covid vaccine, called Spikevax.


The EU’s medicines watchdog said that month it had started to review the new shot.

Moderna said it had also submitted the vaccine to regulators in Australia and Canada and was expecting further authorization decisions in the coming weeks.

The European medical agency is also studying a rival adapted jab developed by Pfizer/BioNTech, which may be approved this autumn.

The Pfizer/BioNTech jab is adapted for the BA.4 and BA.5 subvariants of the virus.

They were first discovered in South Africa and spread rapidly despite high population immunity conferred by prior waves and vaccinations.

Like other Omicron subvariants, they tend to have a milder disease course as they settle less in the lungs and more in the upper nasal passages, causing symptoms such as fever, tiredness and loss of smell.


US medical experts call for Omicron-specific COVID boosters

Moderna CEO says data for Omicron-specific shot likely available in March

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: COVID-19, Moderna vaccine, Omicron, world news
For feedback, complaints, or inquiries, contact us.

Subscribe to our daily newsletter

© Copyright 1997-2022 | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.